Find Midostaurin manufacturers, exporters & distributors on PharmaCompass

Midostaurin

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 10 USDMF, 2 EU WC, 8 NDC API, 14 Listed Suppliers, $ API Reference Price

18 API Suppliers
10 USDMF
2 EU WC
8 NDC API
14 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

15 FDF Dossiers, 5 FDA Orange Book, 1 Canada, 6 Australia, 1 South Africa, 2 Listed Dossiers

15 FDF Dossiers
5 FDA Orange Book
1 Canada
6 Australia
1 South Africa
2 Listed Dossiers

RELATED EXCIPIENT COMPANIES

6 DKSH, 3 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 2 Actylis, 2 BASF, 1 Clariant, 1 Corel Pharma Chem, 1 Finar, 2 Gangwal Chemicals, 1 Kerry, 3 Lonza Capsugel, 1 Pluviaendo, 1 Qualicaps, 2 Roquette, 1 Seppic, 2 Valens Pharmachem

relatedExcipients
6 DKSH
3 Nanjing Well Pharmaceutical
4 ACG Worldwide
2 Actylis
2 BASF
1 Clariant
1 Corel Pharma Chem
1 Finar
2 Gangwal Chemicals
1 Kerry
3 Lonza Capsugel
1 Pluviaendo
1 Qualicaps
2 Roquette
1 Seppic
2 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

8 Empty Capsules, 8 Topical, 7 Coating Systems & Additives, 7 Thickeners and Stabilizers, 7 Solubilizers, 7 Film Formers & Plasticizers, 6 Parenteral, 5 Fillers, Diluents & Binders, 3 Emulsifying Agents, 2 Surfactant & Foaming Agents, 2 Coloring Agents, 1 Granulation, 1 Controlled & Modified Release, 1 Direct Compression, 1 Co-Processed Excipients, 1 Rheology Modifiers, 1 Taste Masking, 1 API Stability Enhancers

excipientsByApplications
8 Empty Capsules
8 Topical
7 Coating Systems & Additives
7 Thickeners and Stabilizers
7 Solubilizers
7 Film Formers & Plasticizers
6 Parenteral
5 Fillers, Diluents & Binders
3 Emulsifying Agents
2 Surfactant & Foaming Agents
2 Coloring Agents
1 Granulation
1 Controlled & Modified Release
1 Direct Compression
1 Co-Processed Excipients
1 Rheology Modifiers
1 Taste Masking
1 API Stability Enhancers

DIGITAL CONTENT

14 NEWS #PharmaBuzz

media
14 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

2 APIs, 2 FDF Dossiers

marketPlace
2 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 2 US Exclusivities

patents
2 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 151,021

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

30,083,178

Annual Reports (USD Million)

Finished Drug Prices

33 RELATED EXCIPIENT COMPANIES

69EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 120685-11-2, Pkc-412, Pkc412, Cgp 41251, 4'-n-benzoylstaurosporine, Pkc 412

Molecular Formula

C₃₅H₃₀N₄O₄

Molecular Weight

570.6 g/mol

InChI Key

BMGQWWVMWDBQGC-IIFHNQTCSA-N

FDA UNII

ID912S5VON

Midostaurin is a synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.

Midostaurin is a Kinase Inhibitor. The mechanism of action of midostaurin is as a Receptor Tyrosine Kinase Inhibitor.

1 2D Structure

Midostaurin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide

2.1.2 InChI

InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1

2.1.3 InChI Key

BMGQWWVMWDBQGC-IIFHNQTCSA-N

2.1.4 Canonical SMILES

CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC

2.1.5 Isomeric SMILES

C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC

2.2 Other Identifiers

2.2.1 UNII

ID912S5VON

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4'-n-benzoyl Staurosporine

2. 4'-n-benzoylstaurosporine

3. Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-n-methyl-, (8alpha,9beta,10beta,12alpha)-

4. Benzoylstaurosporine

5. Cgp 41 251

6. Cgp 41251

7. Cgp-41251

8. N-((9s,10r,11r,13r)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methylbenzamide

9. Pkc 412

10. Pkc-412

11. Pkc412

12. Rydapt

2.3.2 Depositor-Supplied Synonyms

1. 120685-11-2

2. Pkc-412

3. Pkc412

4. Cgp 41251

5. 4'-n-benzoylstaurosporine

6. Pkc 412

7. Rydapt

8. Cgp-41251

9. Benzoylstaurosporine

10. N-benzoylstaurosporine

11. Id912s5von

12. Nvp-pkc412

13. Chembl608533

14. Chebi:63452

15. Nsc-656576

16. N-((9s,10r,11r,13r)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methylbenzamide

17. N-[(5s,6r,7r,9r)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-n-methylbenzamide

18. Midostaurin [inn]

19. Cgp 41 251

20. Midostaurin [usan:inn]

21. Unii-id912s5von

22. Cgp41251

23. Cgp 41231

24. Rydapt (tn)

25. Midostaurin(pkc412)

26. 4-n-benzoylstaurosporine

27. Midostaurin [mi]

28. Staurosporine, N-benzoyl

29. Midostaurin [jan]

30. Midostaurin [usan]

31. Midostaurin [mart.]

32. Midostaurin [who-dd]

33. Midostaurin (jan/usan/inn)

34. Gtpl5702

35. Schembl8295379

36. Midostaurin [orange Book]

37. Hms3229k17

38. Ex-a1741

39. Bdbm50326053

40. Cgp-41521

41. Mfcd00871372

42. Nsc800791

43. S8064

44. Akos024457372

45. Zinc100013130

46. Ccg-101288

47. Cs-3331

48. Db06595

49. Nsc 656576

50. Nsc-800791

51. Ncgc00241102-01

52. Ncgc00241102-02

53. Ncgc00241102-05

54. Ncgc00484987-03

55. Ac-31929

56. Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-n-methyl-, (8alpha,9beta,10beta,12alpha)-

57. Hy-10230

58. C71714

59. D05029

60. J-004379

61. Q6842945

62. Brd-k13646352-001-01-2

63. [9s-(9?,10?,11?,13?)]-n-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-n-methylbenzamide

64. Benzamide, N-((9s,10r,11r,13r)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methyl-

65. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-4-yl]-n-methylbenzamide

66. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-n-methyl-benzamide

67. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-n-methylbenzamide

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₃₅H₃₀N₄O₄
Molecular Weight	570.6 g/mol
XLogP3	4.8
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	570.22670545 g/mol
Monoisotopic Mass	570.22670545 g/mol
Topological Polar Surface Area	77.7 Å²
Heavy Atom Count	43
Formal Charge	0
Complexity	1140
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 1
Drug Name	RYDAPT
Active Ingredient	MIDOSTAURIN
Company	NOVARTIS PHARMS CORP (Application Number: N207997. Patents: 7973031, 8222244, 8575146)

4.2 Drug Indication

Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

FDA Label

Rydapt is indicated:

- in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4. 2);

- as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).

5 Pharmacology and Biochemistry

5.1 Pharmacology

It targets multiple WT and mutated kinases that, when activated, constitutively stimulate aberrant signalling cascades that lead to malignancies such as AML and ASM. Alternative pharmacodynamic effect of midostaurin in prolonging QTc intervals was not clinically significant in patients with advanced SM or AML when compared to placebo. Midostaurin is therapeutically beneficial as a combination therapy for patients undergoing chemotherapy.

5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

MIDOSTAURIN

5.3.2 FDA UNII

ID912S5VON

5.3.3 Pharmacological Classes

Receptor Tyrosine Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]

5.4 ATC Code

L01XE

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX10 - Midostaurin

5.5 Absorption, Distribution and Excretion

Absorption

The time to reach maximum concentration ranges from 1-3 hrs in fasting patients. The maximum concentration and the time it takes to reach this concentration is reduced up to 20% in presence of a standard meal.

Route of Elimination

Accounting for 95% of recovered dose eliminated through fecal excretion, 91% was determined as metabolites and 4% as unchanged parent drug. Remaining 5% of the recovered dose is eliminated via renal excretion.

Volume of Distribution

The Vd of midostaurin is 95.2L. The parent drug and its main metabolites (CGP62221, CGP52421) are distributed in plasma in vitro.

Clearance

The clearance values of during the initial formation of metabolites are 1.47 L/h for CGP62221 metabolite and 0.501 L/h for CGP52421. 28 days following the oral administration of midostaurin, the clearance of CGP52421 may increase up to 5.2 fold in a recommended dose of 25 mg, resulting in a 2.1- to 2.5-fold increase in total clearance of midostaurin.

5.6 Metabolism/Metabolites

Midostaurin is primarily metabolized into CGP62221 and CGP52421 via hepatic CYP3A4 enzymatic activity. The metabolism of CGP62221 takes place initially in a linear relationship whereas CGP52421 formation is an inducible process.

5.7 Biological Half-Life

Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs for CGP52421.

5.8 Mechanism of Action

It potently inhibits multiple receptor tyrosine kinases. Midostaurin and its major active metabolites CGP62221 and CGP52421 inhibit the activity of protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine kinases. Inhibition of FLT3 receptor signalling cascades induces apoptosis of target leukemia cells expressing target receptors and mast cells, in addition to its antiproliferative activity toward multiple cancer cell lines. Midostaurin also interacts with organic anion transporter (OATP) 1A1 and multidrug resistance protein (MRP)-2 according to preliminary in vitro studies.

API SUPPLIERS

01

Farmhispania

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF EU

AUDIT

Corporate PDF

02

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #12.1F43

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

05

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Taiwan

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC

KDMF VMF Others AUDIT

06

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

07

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

08

Hubei Honch Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

09

Procos

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

10

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Dr Reddys Laboratories Ltd

India

Medlab Asia & Asia Health

Not Confirmed

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

India

Virtual Booth

Digital Content

Midostaurin

GDUFA

DMF Review : Complete

Rev. Date : 2020-10-26

Pay. Date : 2020-09-21

DMF Number : 34665

Submission : 2020-03-31

Status : Active

Type : II

02

Dr Reddys Laboratories Ltd

India

Medlab Asia & Asia Health

Not Confirmed

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

India

Virtual Booth

Digital Content

Midostaurin Amorphous

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35231

Submission : 2020-09-28

Status : Active

Type : II

03

Chunghwa Chemical Synthesis And Biot...

Taiwan

Medlab Asia & Asia Health

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Taiwan

Virtual Booth

Digital Content

Midostaurin

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36640

Submission : 2021-12-29

Status : Active

Type : II

04

Brightgene Bio-medical Technology Co...

China

Medlab Asia & Asia Health

Not Confirmed

05

Concord Biotech Ltd

India

Medlab Asia & Asia Health

Not Confirmed

06

Hetero Labs Ltd

India

Medlab Asia & Asia Health

Not Confirmed

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652812200,"product":"MIDOSTAURIN BNO. DDD231004031 MFGDT: 23.","address":"1482 1486 TRASAD ROAD,DHOLKA","city":"AHMEDABAD,GUJARAT","supplier":"CONCORD BIOTECH","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"ACTAVIS INC","customerCountry":"TAIWAN","quantity":"0.00","actualQuantity":"1.275","unit":"GMS","unitRateFc":"654.1","totalValueFC":"737.5","currency":"USD","unitRateINR":44705.882352941182,"date":"18-May-2022","totalValueINR":"57000","totalValueInUsd":"737.5","indian_port":"AHMEDABAD AIR","hs_no":"29420090","bill_no":"1477311","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"1482 1486 TRASAD ROAD,DHOLKA, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686767400,"product":"MIDOSTAURIN BATCH NO.1955A223002,MFG.DT.","address":"1482 1486 TRASAD ROAD,DHOLKA","city":"AHMEDABAD,GUJARAT","supplier":"CONCORD BIOTECH","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO ORDER","customerCountry":"TAIWAN","quantity":"2.10","actualQuantity":"2.1","unit":"KGS","unitRateFc":"52000","totalValueFC":"108411.2","currency":"USD","unitRateINR":4243333.3799999999,"date":"15-Jun-2023","totalValueINR":"8911000.098","totalValueInUsd":"108411.2","indian_port":"AHMEDABAD AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"1482 1486 TRASAD ROAD,DHOLKA, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642962600,"product":"PKC412 [MIDOSTAURIN] DRUG SUBSTANCE [DRUG LICENCE NO : TL\/HZ\/21\/000358 DT : 21.01.2021]","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"SANDOZ B2B","supplierCountry":"SLOVENIA","foreign_port":"LJUBLJANA - BRNIK","customer":"NOVARTIS PHARMACEUTICALS CORPORATION","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"3477.3","totalValueFC":"20095.3","currency":"EUR","unitRateINR":"299393","date":"24-Jan-2022","totalValueINR":"1496964.74","totalValueInUsd":"20095.3","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"7208013","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"LJUBLJANA - BRNIK","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"}]